Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 50 of 52

    1.

    Cancer awareness in atypical thrombotic microangiopathies.

    Oberic L, Buffet M, Schwarzinger M, Veyradier A, Clabault K, Malot S, Schleinitz N, Valla D, Galicier L, Bengrine-Lefèvre L, Gorin NC, Coppo P; Reference Center for the Management of Thrombotic Microangiopathies.

    Oncologist. 2009 Aug;14(8):769-79. Epub 2009 Aug 14.PMID: 19684072 [PubMed - in process]Related articles

    2.

    IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura.

    Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheiflinger F.

    J Thromb Haemost. 2009 Oct;7(10):1703-10. Epub 2009 Aug 11.PMID: 19682238 [PubMed - in process]Related articles

    3.

    Thrombotic microangiopathies: towards a pathophysiology-based classification.

    Coppo P, Veyradier A.

    Cardiovasc Hematol Disord Drug Targets. 2009 Mar;9(1):36-50. Review.PMID: 19275576 [PubMed - indexed for MEDLINE]Related articles

    4.

    Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity.

    Malak S, Wolf M, Millot GA, Mariotte E, Veyradier A, Meynard JL, Korach JM, Malot S, Bussel A, Azoulay E, Boulanger E, Galicier L, Devaux E, Eschwège V, Gallien S, Adrie C, Schlemmer B, Rondeau E, Coppo P; Réseau d'Etude des Microangiopathies Thrombotiques (TMA-Rare Diseases Reference Center).

    Scand J Immunol. 2008 Sep;68(3):337-44.PMID: 18782260 [PubMed - indexed for MEDLINE]Related articles

    5.

    Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.

    Loirat C, Girma JP, Desconclois C, Coppo P, Veyradier A.

    Pediatr Nephrol. 2009 Jan;24(1):19-29. Epub 2008 Jun 24. Review.PMID: 18574602 [PubMed - indexed for MEDLINE]Related articles

    6.

    Molecular characterization of four ADAMTS13 mutations responsible for congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).

    Hommais A, Rayes J, Houllier A, Obert B, Legendre P, Veyradier A, Girma JP, Ribba AS.

    Thromb Haemost. 2007 Sep;98(3):593-9.PMID: 17849048 [PubMed - indexed for MEDLINE]Related articles

    7.

    von Willebrand factor collagen binding assay with a commercial kit using type III collagen in von Willebrand disease type 2.

    Veyradier A, Trossaert M, Lefrancois A, Fressinaud E, Meyer D.

    J Thromb Haemost. 2007 Apr;5(4):868-70. No abstract available. PMID: 17408416 [PubMed - indexed for MEDLINE]Related articles

    8.

    [Hereditary hemolytic uremic syndromes and thrombotic thrombocytopenic purpura]

    Loirat C, Sellier-Leclerc AL, Frémeaux-Bacchi V, Dragon-Durey A, Girma JP, Veyradier A.

    Nephrol Ther. 2006 Jan;2 Suppl 2:S149-61. Review. French. PMID: 17373216 [PubMed - indexed for MEDLINE]Related articles

    9.

    From humoral rejection to generalized thrombotic microangiopathy--role of acquired ADAMTS13 deficiency in a renal allograft recipient.

    Ulinski T, Charpentier A, Colombat M, Desconclois C, Mougenot B, Fremaux-Bacchi V, Suberbielle C, Deschênes G, Bensman A, Veyradier A.

    Am J Transplant. 2006 Dec;6(12):3030-6. Erratum in: Am J Transplant. 2007 Mar;7(3):730. PMID: 17294528 [PubMed - indexed for MEDLINE]Related articles

    10.

    Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS13 inhibitor.

    Schleinitz N, Ebbo M, Mazodier K, Poullin P, Bernit E, Veit V, Veyradier A, Fakhouri F, Kaplanski G, Harle JR.

    Am J Hematol. 2007 May;82(5):417-8. No abstract available. PMID: 17266057 [PubMed - indexed for MEDLINE]Related articles

    11.

    Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity.

    Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, Girma JP, Azoulay E, Brun-Buisson C, Fakhouri F, Mira JP, Oksenhendler E, Poullin P, Rondeau E, Schleinitz N, Schlemmer B, Teboul JL, Vanhille P, Vernant JP, Meyer D, Veyradier A; French Clinical and Biological Network on Adult Thrombotic Microangiopathies.

    Blood. 2007 Apr 1;109(7):2815-22.PMID: 17164349 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    [Acquired idiopathic thrombotic thrombocytopenic purpura: arguments for an autoimmune disease]

    Coppo P, Veyradier A, Monge M; Réseau d'Etude des Microangiopathies Thrombotiques.

    Presse Med. 2006 Dec;35(12 Pt 2):1876-86. Review. French. PMID: 17159713 [PubMed - indexed for MEDLINE]Related articles

    13.

    Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13.

    Rayes J, Hommais A, Legendre P, Tout H, Veyradier A, Obert B, Ribba AS, Girma JP.

    J Thromb Haemost. 2007 Feb;5(2):321-8. Epub 2006 Nov 1.PMID: 17087728 [PubMed - indexed for MEDLINE]Related articles

    14.

    Thrombotic microangiopathy with acquired deficiency in ADAMTS 13 activity in lung transplant recipients.

    Mal H, Veyradier A, Brugière O, Da Silva D, Colombat M, Azoulay E, Benayoun L, Rondeau E, Dauriat G, Taillé C, Lesèche G, Castier Y, Fournier M.

    Transplantation. 2006 Jun 27;81(12):1628-32.PMID: 16794526 [PubMed - indexed for MEDLINE]Related articles

    15.

    Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange.

    Darmon M, Azoulay E, Thiery G, Ciroldi M, Galicier L, Parquet N, Veyradier A, Le Gall JR, Oksenhendler E, Schlemmer B.

    Crit Care Med. 2006 Aug;34(8):2127-33.PMID: 16763519 [PubMed - indexed for MEDLINE]Related articles

    16.

    Comparison of FRETS-VWF73 to full-length VWF as a substrate for ADAMTS13 activity measurement in human plasma samples.

    Mahdian R, Rayes J, Girma JP, Houllier A, Obert B, Meyer D, Veyradier A.

    Thromb Haemost. 2006 Jun;95(6):1049-51. No abstract available. PMID: 16732393 [PubMed - indexed for MEDLINE]Related articles

    17.

    Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children.

    Loirat C, Veyradier A, Girma JP, Ribba AS, Meyer D.

    Semin Thromb Hemost. 2006 Mar;32(2):90-7. Review.PMID: 16575683 [PubMed - indexed for MEDLINE]Related articles

    18.

    Desmopressin, an unexpected link between nocturnal enuresis and inherited thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).

    Veyradier A, Meyer D, Loirat C.

    J Thromb Haemost. 2006 Mar;4(3):700-1. No abstract available. PMID: 16460464 [PubMed - indexed for MEDLINE]Related articles

    19.

    Screening for bleeding disorders in women with menorrhagia using a platelet function analyzer.

    Veyradier A, Gervaise A, Boyer-Neumann C, Wolf M, Fernandez H.

    J Thromb Haemost. 2006 Feb;4(2):483-5. No abstract available. PMID: 16420588 [PubMed - indexed for MEDLINE]Related articles

    20.

    Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura.

    Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, Bordessoule D, Pène F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B; Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte.

    Br J Haematol. 2006 Jan;132(1):66-74. Review.PMID: 16371021 [PubMed - indexed for MEDLINE]Related articles

    21.

    A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B.

    Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ.

    Blood. 2005 Nov 1;106(9):3035-42. Epub 2005 Jul 12.PMID: 16014562 [PubMed - indexed for MEDLINE]Related articlesFree article

    22.

    Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.

    Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P, Deroure B, Delarue R, Lesavre P, Vanhille P, Hermine O, Remuzzi G, Grünfeld JP.

    Blood. 2005 Sep 15;106(6):1932-7. Epub 2005 Jun 2.PMID: 15933059 [PubMed - indexed for MEDLINE]Related articlesFree article

    23.

    Thrombotic thrombocytopenic purpura and its diagnosis.

    Veyradier A, Meyer D.

    J Thromb Haemost. 2005 Nov;3(11):2420-7. Epub 2005 May 9. Review. No abstract available. PMID: 15892859 [PubMed - indexed for MEDLINE]Related articles

    24.

    Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome.

    Amoura Z, Costedoat-Chalumeau N, Veyradier A, Wolf M, Ghillani-Dalbin P, Cacoub P, Meyer D, Piette JC.

    Arthritis Rheum. 2004 Oct;50(10):3260-4.PMID: 15476241 [PubMed - indexed for MEDLINE]Related articlesFree article

    25.

    Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.

    Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA, Malot S, Heshmati F, Mira JP, Boulanger E, Galicier L, Durey-Dragon MA, Frémeaux-Bacchi V, Ramakers M, Pruna A, Bordessoule D, Gouilleux V, Scrobohaci ML, Vernant JP, Moreau D, Azoulay E, Schlemmer B, Guillevin L, Lassoued K; Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte.

    Medicine (Baltimore). 2004 Jul;83(4):233-44.PMID: 15232311 [PubMed - indexed for MEDLINE]Related articles

    26.

    Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).

    Veyradier A, Lavergne JM, Ribba AS, Obert B, Loirat C, Meyer D, Girma JP.

    J Thromb Haemost. 2004 Mar;2(3):424-9.PMID: 15009458 [PubMed - indexed for MEDLINE]Related articles

    27.

    Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide.

    Fakhouri F, Teixeira L, Delarue R, Grünfeld JP, Veyradier A.

    Ann Intern Med. 2004 Feb 17;140(4):314-5. No abstract available. Erratum in: Ann Intern Med. 2004 May 4;140(9):767. PMID: 14970167 [PubMed - indexed for MEDLINE]Related articlesFree article

    28.

    Assays of ADAMTS-13 activity.

    Veyradier A, Girma JP.

    Semin Hematol. 2004 Jan;41(1):41-7. Review.PMID: 14727258 [PubMed - indexed for MEDLINE]Related articles

    29.

    Multi-therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease.

    Boyer-Neumann C, Dreyfus M, Wolf M, Veyradier A, Meyer D.

    J Thromb Haemost. 2003 Jan;1(1):190-2. No abstract available. PMID: 12871560 [PubMed - indexed for MEDLINE]Related articles

    30.

    Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome.

    Veyradier A, Obert B, Haddad E, Cloarec S, Nivet H, Foulard M, Lesure F, Delattre P, Lakhdari M, Meyer D, Girma JP, Loirat C.

    J Pediatr. 2003 Mar;142(3):310-7. Erratum in: J Pediatr. 2003 Jun;142(6):616. Loriat, C [corrected to Loirat, C]. PMID: 12640381 [PubMed - indexed for MEDLINE]Related articles

    31.

    High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome.

    Coppo P, Bussel A, Charrier S, Adrie C, Galicier L, Boulanger E, Veyradier A, Leblanc T, Alberti C, Azoulay E, Le Gall JR, Schlemmer B.

    Medicine (Baltimore). 2003 Jan;82(1):27-38.PMID: 12544708 [PubMed - indexed for MEDLINE]Related articles

    32.

    [Plasma exchanges and replacement fluids for adult thrombotic microangiopathy. Synopsis of the Round table held on May 3, 2001]

    Courtois F, Coffe C, Coppo P, Korach JM, Tremisi JP, Bussel A, Driss F, Guidet B, Piquet Y, Pourrat J, Riffle G, Veyradier A, Vignon D.

    Ann Med Interne (Paris). 2002 Oct;153(6):416-8. French. No abstract available. PMID: 12486394 [PubMed - indexed for MEDLINE]Related articles

    33.

    Plasma therapy in von Willebrand factor protease deficiency.

    Deschênes G, Veyradier A, Cloarec S, Benoit S, Desbois I, Gruel Y, Nivet H.

    Pediatr Nephrol. 2002 Oct;17(10):867-70. Epub 2002 Aug 16.PMID: 12376819 [PubMed - indexed for MEDLINE]Related articles

    34.

    [Pathophysiology of thrombotic microangiopathies: current understanding]

    Coppo P, Veyradier A, Durey MA, Fremeaux-Bacchi V, Scrobohaci ML, Amesland F, Bussel A.

    Ann Med Interne (Paris). 2002 May;153(3):153-66. Review. French. PMID: 12218898 [PubMed - indexed for MEDLINE]Related articles

    35.

    Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency.

    Blot E, Decaudin D, Veyradier A, Bardier A, Zagame OL, Pouillart P.

    Thromb Res. 2002 Apr 15;106(2):127-30.PMID: 12182911 [PubMed - indexed for MEDLINE]Related articles

    36.

    Complete defect in vWF-cleaving protease activity associated with increased shear-induced platelet aggregation in thrombotic microangiopathy.

    Ajzenberg N, Denis CV, Veyradier A, Girma JP, Meyer D, Baruch D.

    Thromb Haemost. 2002 May;87(5):808-11.PMID: 12038781 [PubMed - indexed for MEDLINE]Related articles

    37.

    Total deficiency of specific von Willebrand factor-cleaving protease and recovery following plasma therapy in one patient with hemolytic-uremic syndrome.

    Veyradier A, Brivet F, Wolf M, Boyer-Neumann C, Obert B, Girma JP, Meyer D.

    Hematol J. 2001;2(5):352-4. No abstract available. PMID: 11920271 [PubMed - indexed for MEDLINE]Related articles

    38.

    Selective inactivation of Von Willebrand factor binding to glycoprotein IIb/IIIa and to inhibitor monoclonal antibody 9 by site-directed mutagenesis.

    Jumilly AL, Veyradier A, Ribba AS, Meyer D, Girma JP.

    Hematol J. 2001;2(3):180-7.PMID: 11920243 [PubMed - indexed for MEDLINE]Related articles

    39.

    Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.

    Veyradier A, Obert B, Houllier A, Meyer D, Girma JP.

    Blood. 2001 Sep 15;98(6):1765-72.PMID: 11535510 [PubMed - indexed for MEDLINE]Related articlesFree article

    40.

    Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract.

    Veyradier A, Balian A, Wolf M, Giraud V, Montembault S, Obert B, Dagher I, Chaput JC, Meyer D, Naveau S.

    Gastroenterology. 2001 Feb;120(2):346-53.PMID: 11159874 [PubMed - indexed for MEDLINE]Related articles

    41.

    Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension.

    Veyradier A, Nishikubo T, Humbert M, Wolf M, Sitbon O, Simonneau G, Girma JP, Meyer D.

    Circulation. 2000 Nov 14;102(20):2460-2.PMID: 11076816 [PubMed - indexed for MEDLINE]Related articlesFree article

    42.

    von Willebrand factor ristocetin cofactor activity correlates with platelet function in a high shear stress system.

    Veyradier A, Fressinaud E, Boyer-Neumann C, Trossaert M, Meyer D.

    Thromb Haemost. 2000 Oct;84(4):727-8. No abstract available. PMID: 11057880 [PubMed - indexed for MEDLINE]Related articles

    43.

    Acquired von Willebrand syndrome: from pathophysiology to management.

    Veyradier A, Jenkins CS, Fressinaud E, Meyer D.

    Thromb Haemost. 2000 Aug;84(2):175-82. Review. No abstract available. PMID: 10959686 [PubMed - indexed for MEDLINE]Related articles

    44.

    Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF.

    Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP.

    Thromb Haemost. 1999 Nov;82(5):1382-5.PMID: 10595622 [PubMed - indexed for MEDLINE]Related articles

    45.

    Prothrombin 20210G/A mutation in two patients with mesenteric ischemia.

    Balian A, Veyradier A, Naveau S, Wolf M, Montembault S, Giraud V, Borotto E, Henry C, Meyer D, Chaput JC.

    Dig Dis Sci. 1999 Sep;44(9):1910-3.PMID: 10505734 [PubMed - indexed for MEDLINE]Related articles

    46.

    Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates.

    Fressinaud E, Veyradier A, Sigaud M, Boyer-Neumann C, Le Boterff C, Meyer D.

    Br J Haematol. 1999 Sep;106(3):777-83.PMID: 10468873 [PubMed - indexed for MEDLINE]Related articles

    47.

    New assay for measuring binding of platelet glycoprotein IIb/IIIa to unpurified von Willebrand factor.

    Veyradier A, Jumilly AL, Ribba AS, Obert B, Houllier A, Meyer D, Girma JP.

    Thromb Haemost. 1999 Jul;82(1):134-9.PMID: 10456467 [PubMed - indexed for MEDLINE]Related articles

    48.

    [Evaluation of a new automated method for von Willebrand factor antigen measurement: the STA-Liatest vWF]

    Veyradier A, Fressinaud E, Sigaud M, Wolf M, Meyer D.

    Ann Biol Clin (Paris). 1999 May;57(3):364-8. French. No abstract available. PMID: 10377492 [PubMed - indexed for MEDLINE]Related articlesFree article

    49.

    A new automated method for von Willebrand factor antigen measurement using latex particles.

    Veyradier A, Fressinaud E, Sigaud M, Wolf M, Meyer D.

    Thromb Haemost. 1999 Feb;81(2):320-1. No abstract available. PMID: 10064018 [PubMed - indexed for MEDLINE]Related articles

    50.

    Laboratory diagnosis of von Willebrand disease.

    Veyradier A, Fressinaud E, Meyer D.

    Int J Clin Lab Res. 1998;28(4):201-10. Review.PMID: 9879492 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Find related data

    Search details

    » See more...